Furaprevir

伏拉瑞韦

Report date: 2025/08/12 20:00:05
NME

Base Information

Drug NameFuraprevir
Drug Alias Namefuraprevir夫雷瑞韦furaprevirumTG-2349
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesTaiGen Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesTaiGen Biotechnology Co LtdDongguan Hec Taigen Biopharmaceuticals Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A